197 related articles for article (PubMed ID: 23070145)
1. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
Hsyu PH; Mould DR; Upton RN; Amantea M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
[TBL] [Abstract][Full Text] [Related]
2. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
Hsyu PH; Mould DR; Abbas R; Amantea M
Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
[TBL] [Abstract][Full Text] [Related]
4. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
[TBL] [Abstract][Full Text] [Related]
5. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Keller-V Amsberg G; Brümmendorf TH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
[TBL] [Abstract][Full Text] [Related]
12. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
13. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Abbas R; Leister C; Sonnichsen D
Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
Abbas R; Hsyu PH
Clin Pharmacokinet; 2016 Oct; 55(10):1191-1204. PubMed ID: 27113346
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
[TBL] [Abstract][Full Text] [Related]
18. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Abbas R; Boni J; Sonnichsen D
Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
[TBL] [Abstract][Full Text] [Related]
20. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
